Lenvatinib
Nonpapillary Renal Cell Carcinoma
Explore 112 assets in Nonpapillary Renal Cell Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07460206CT.gov Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment | — | Not Yet Recruiting | — | — | — |
NCT07383441CT.gov Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | — | Recruiting | — | — | — |
NCT07571551CT.gov Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT07256223CT.gov A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | — | Not Yet Recruiting | — | — | — |
NCT07389629CT.gov Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | — | Recruiting | — | — | — |
NCT07097935CT.gov Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06138496CT.gov Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | — | Completed | — | — | — |
NCT06035224CT.gov Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05012371CT.gov Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | — | Active Not Recruiting | — | — | — |
Show 1 more trialShow fewer
NCT04977453CT.gov GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nonpapillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenvatinib (this asset) | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | B · 62 |
| Girentuximab | Massachusetts General Hospital | P3 | BB |
| Pazopanib | Academic and Community Cancer Research United | P4 | BB |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P3 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P3 | BB |
| Cabozantinib | SWOG Cancer Research Network | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P3 | B |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
+42 more in the Nonpapillary Renal Cell Carcinoma cohort
Other indications for Lenvatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Portal Vein Thrombosis | — | P4 | BBB · 73 |
| Ovarian Carcinoma | — | P4 | BB · 70 |
| Hepatocellular Carcinoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GirentuximabMassachusetts General HospitalBB
- PazopanibAcademic and Community Cancer Research UnitedBB
- Clostridium Butyricum Miyairi 588City of Hope Medical CenterBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- NivolumabFred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. Lenvatinib in Nonpapillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenvatinib-nonpapillary-renal-cell-carcinoma-114585
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →